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Purpose
Programmed death ligand 1 (PD-L1) plays an important
role in controlling autoreactive and follicular T helper
lymphocytes, which can induce autoantibody production.
Properly expressed PD-L1 thus prevents autoimmune
disease. Induced by inflammatory cytokines, PD-L1 is ele-
vated on monocytes from patients with infections and
rheumatoid arthritis, but is poorly expressed on mono-
cytes from SLE patients with active disease. Our goal was
to define the mechanism for PD-L1 dysregulation in
pediatric patients with SLE, and to clinically characterize
those patients with loss of PD-L1.
Methods
Serial samples were obtained from 26 pediatric patients
with SLE (20 samples during active disease, SELENA-SLE-
DAI score >4, and 37 during remission) and 28 age-
matched controls. PD-L1 expression on CD11c+ CD14high
monocytes was assayed in cultured peripheral blood cells
by flow cytometry. Cytokines in culture supernatants were
assayed by multiplex ELISA.
Results
PD-L1 expression on healthy control monocytes was 2.7-
fold higher than SLE patients with active disease (mean
induction 28.7, SD 17.7, versus 10.5, SD 11.4, p<0.005).
Overall, SLE patients in remission expressed normal levels
of PD-L1 on monocytes (mean 24.2, SD 16.5, p<0.0005
versus active SLE). PD-L1 surface expression was induced
on a mean of 80% of healthy monocytes, compared to
patients with active SLE (mean 52%, p=0.00003). ROC
curves demonstrated the ability of PD-L1 to distinguish
between active and inactive disease (AUC 0.75) and
between active SLE and healthy controls (AUC 0.79). The
effect was most pronounced in patients without renal dis-
ease; patients with any history of renal disease did not
restore monocyte PD-L1. Patients in remission with pre-
vious renal disease had a50% of the PD-L1 expression of
those in remission who never had renal disease (mean
14.0 vs. 29.1, p=0.02). Non-renal patients restored PD-L1
fully during remission, and disease activity correlated with
PDL1 expression (Spearman correlation r= -0.38, P=0.02).
PD-L1 expression on active SLE monocytes could be
restored by healthy cells producing IL-10 and/or TNF-a.
Conversely, PD-L1 expression on healthy monocytes was
suppressed by TGF-b, which SLE cells over-expressed.
Conclusion
During an inflammatory response patients with SLE are
lacking a key step to limit autoreactive lymphocyte activity:
the local, cytokine-mediated induction of PD-L1 expres-
sion on antigen presenting cells. Moreover, therapeutic
agents that inhibit TNF-a may induce autoantibodies in
part by preventing PD-L1 induction, thereby impeding an
important mechanism of T and B lymphocyte regulation.
Patients with a persistent defect in PD-L1 expression may
be prone to more severe disease, leading to glomerulone-
phritis, whereas patients who can express PD-L1 after
immunosuppressive therapy can resolve autoantibody pro-
duction, preventing the progression toward renal disease.
Infection and other autoimmune diseases may potentially
be distinguished from active non-renal SLE on the basis of
monocyte PD-L1 expression.
Disclosure
Anne M. Stevens: None; Jing-Ni Ou: None.
2University of Washington, Seattle, WA, USA
Full list of author information is available at the end of the article
Stevens and Ou Pediatric Rheumatology 2012, 10(Suppl 1):A2
http://www.ped-rheum.com/content/10/S1/A2
© 2012 Stevens and Ou; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Author details
1Seattle Children’s Research Institute, Seattle, WA, USA. 2University of
Washington, Seattle, WA, USA.
Published: 13 July 2012
doi:10.1186/1546-0096-10-S1-A2
Cite this article as: Stevens and Ou: PD-L1 expression on monocytes
marks active systemic lupus erythematosus in patients without
nephritis. Pediatric Rheumatology 2012 10(Suppl 1):A2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Stevens and Ou Pediatric Rheumatology 2012, 10(Suppl 1):A2
http://www.ped-rheum.com/content/10/S1/A2
Page 2 of 2
